Olaratumab and doxorubicin versus doxorubicin alone in soft tissue sarcoma

BACKGROUND: Median overall survival for patients with metastatic soft tissue sarcoma is 12 to 16 months. Olaratumab is a human anti–platelet-derived growth factor receptor α monoclonal antibody which has antitumour activity in human sarcoma xenografts. METHODS: We conducted an open-label phase 1b, r...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Lancet
Hoofdauteurs: Tap, William D., Jones, Robin L., Van Tine, Brian A., Chmielowski, Bartosz, Elias, Anthony D., Adkins, Douglas, Agulnik, Mark, Cooney, Matthew M., Livingston, Michael B., Pennock, Gregory, Hameed, Meera R., Shah, Gaurav D., Qin, Amy, Shahir, Ashwin, Cronier, Damien M., Ilaria, Robert, Conti, Ilaria, Cosaert, Jan, Schwartz, Gary K.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2016
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5647653/
https://ncbi.nlm.nih.gov/pubmed/27291997
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(16)30587-6
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items